We are excited to share that Vivien Ibironke Ibiyemi joined the TEQCool team as Chief Operating Officer a few weeks ago. This is significant for TEQCool as Vivien comes with a lot of experience from within Medtech and product development in different companies within both R & D and Operations. In this newsletter, we are interviewing Vivien to find out some interesting facts regarding the business development, and how the company is building its value through interviews with key opinion leaders.
Vivien, could you tell us what is happening at TEQCool?
Since joining TEQCool in December 2024, my mission has been clear: to strengthen the foundation of our groundbreaking brain cooling technology while positioning TEQCool as a leader in personalized medicine. As we step into a new year, I am excited to share the incredible progress TEQCool has made since I joined as COO in December. Our journey to revolutionize targeted brain cooling technology has gained significant momentum, and I am proud of the strides we have taken as a team.
How are you working to position the company and the product?
One of our core strategies is to gather insights from leading neurosurgeons to ensure that our solutions address real-world challenges in neurocritical care. Recent interviews with renowned neurosurgeons, including Dr. Niklas Marklund (Sweden) and Dr. Bunmi Ogunrin (UK), have provided invaluable perspectives on the critical need for targeted brain cooling in the medical field.
Here are key findings from these interviews:
- Targeted Cooling as a Game-Changer: Both experts emphasized that targeted brain cooling addresses critical challenges in managing conditions like traumatic brain injury, status epilepticus, and subarachnoid hemorrhage.
- Personalized Medicine in Focus, A Strategic Advantage: The neurosurgeons emphasized the importance of targeted temperature management as a personalized and safer alternative to systemic cooling. Personalized, localized cooling aligns with modern medical trends, offering safer and more effective solutions compared to systemic cooling. This aligns perfectly with TEQCool’s vision of delivering precise, patient-specific solutions that reduce systemic risks and improve outcomes. This approach is not only a marketing strategy but also a cornerstone of our product’s unique value proposition. By targeting brain cooling specifically, we aim to revolutionize how neurocritical conditions are treated, providing unmatched benefits to patients, clinicians, and healthcare systems.
- High Demand in Neurocritical Care: Their feedback reinforces the high demand for our technology in neurocritical care, in conditions such as traumatic brain injury (TBI), subarachnoid hemorrhage, and status epilepticus were identified as key areas where our technology could significantly improve outcomes by reducing fever, intracranial pressure (ICP) and cerebral edema.
- Market Need for Innovation: Current cooling solutions are invasive, slow, can’t target the brain, cools the entire body and pose systemic risks like infections. TEQCool’s non-invasive, precise brain cooling system is uniquely positioned to fill this critical gap.
The insights from these interviews are not just validating our approach but are also fueling our business case development as we aggressively continue engaging with experts in neurology and neurosurgery. Each conversation adds depth to our understanding of the market and strengthens our strategy to deliver impactful, patient-centered solutions.
This sounds really interesting, but how can you use this to build the value of TEQCool?
The insights gathered from leading neurosurgeons are actively being used to solidify our business case, ensuring that our technology resonates with investors, shareholders, and healthcare providers as we demonstrate the unmet need for our technology. We are building a compelling narrative around the life-saving potential of targeted brain cooling and how it will transform care delivery.
By aligning their feedback with our development goals, we are demonstrating the practicality, safety, and efficacy of our system. This robust, evidence-based case is designed to attract investment and support from all stakeholders.
